Medicare part D prescription drug program: benefits, unintended consequences and impact on health disparities.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Pharmaceutical policies: effects of regulating drug insurance schemes.The Cochrane database of systematic reviews · 2022
   Pooled it
2. Is patient insurance type related to physician recommendation, administration and referral for adult vaccination? A survey of US physicians.Human vaccines & immunotherapeutics · 2019
   Article
3. Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use.Pharmacoepidemiology and drug safety · 2016
   Article
4. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.Journal of managed care & specialty pharmacy · 2016
   Article

Corrections and comments

• Comment on
  Cost sharing and decreased branded oral anti-diabetic medication adherence among elderly Part D Medicare beneficiaries.2013

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as